Multiple, Linked Human Immunodeficiency Virus Type 1 Drug Resistance Mutations in Treatment-Experienced Patients Are Missed by Standard Genotype Analysis

ABSTRACT To investigate the extent to which drug resistance mutations are missed by standard genotyping methods, we analyzed the same plasma samples from 26 patients with suspected multidrug-resistant human immunodeficiency virus type 1 by using a newly developed single-genome sequencing technique and compared it to standard genotype analysis. Plasma samples were obtained from patients with prior exposure to at least two antiretroviral drug classes and who were on a failing antiretroviral regimen. Standard genotypes were obtained by reverse transcriptase (RT)-PCR and sequencing of the bulk PCR product. For single-genome sequencing, cDNA derived from plasma RNA was serially diluted to 1 copy per reaction, and a region encompassing p6, protease, and a portion of RT was amplified and sequenced. Sequences from 15 to 46 single viral genomes were obtained from each plasma sample. Drug resistance mutations identified by single-genome sequencing were not detected by standard genotype analysis in 24 of the 26 patients studied. Mutations present in less than 10% of single genomes were almost never detected in standard genotypes (1 of 86). Similarly, mutations present in 10 to 35% of single genomes were detected only 25% of the time in standard genotypes. For example, in one patient, 10 mutations identified by single-genome sequencing and conferring resistance to protease inhibitors (PIs), nucleoside analog reverse transcriptase inhibitors, and nonnucleoside reverse transcriptase inhibitors (NNRTIs) were not detected by standard genotyping methods. Each of these mutations was present in 5 to 20% of the 20 genomes analyzed; 15% of the genomes in this sample contained linked PI mutations, none of which were present in the standard genotype. In another patient sample, 33% of genomes contained five linked NNRTI resistance mutations, none of which were detected by standard genotype analysis. These findings illustrate the inadequacy of the standard genotype for detecting low-frequency drug resistance mutations. In addition to having greater sensitivity, single-genome sequencing identifies linked mutations that confer high-level drug resistance. Such linkage cannot be detected by standard genotype analysis.

[1]  C. Charpentier,et al.  Role of Minority Populations of Human Immunodeficiency Virus Type 1 in the Evolution of Viral Resistance to Protease Inhibitors , 2004, Journal of Virology.

[2]  R. Shafer,et al.  Interlaboratory concordance of DNA sequence analysis to detect reverse transcriptase mutations in HIV-1 proviral DNA. ACTG Sequencing Working Group. AIDS Clinical Trials Group. , 1998, Journal of virological methods.

[3]  S. Hammer,et al.  Antiretroviral therapy for HIV infection in 1998: updated recommendations of the International AIDS Society-USA Panel. , 1997, JAMA.

[4]  L. Loeb,et al.  Fidelity of HIV-1 reverse transcriptase. , 1988, Science.

[5]  D. Richman,et al.  Comparative performance of high-density oligonucleotide sequencing and dideoxynucleotide sequencing of HIV type 1 pol from clinical samples. , 1998, AIDS Research and Human Retroviruses.

[6]  L. Bacheler,et al.  Human Immunodeficiency Virus Type 1 Mutations Selected in Patients Failing Efavirenz Combination Therapy , 2000, Antimicrobial Agents and Chemotherapy.

[7]  J. Margolick,et al.  Consistent Viral Evolutionary Changes Associated with the Progression of Human Immunodeficiency Virus Type 1 Infection , 1999, Journal of Virology.

[8]  J. Condra,et al.  In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors , 1995, Nature.

[9]  T. Merigan,et al.  Human Immunodeficiency Virus Type 1 Protease Genotypes and In Vitro Protease Inhibitor Susceptibilities of Isolates from Individuals Who Were Switched to Other Protease Inhibitors after Long-Term Saquinavir Treatment , 1998, Journal of Virology.

[10]  P. Simmonds,et al.  Detection, quantification and sequencing of HIV-1 from the plasma of seropositive individuals and from factor VIII concentrates. , 1991, AIDS.

[11]  J. Thompson,et al.  CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. , 1994, Nucleic acids research.

[12]  L. M. Mansky,et al.  Lower in vivo mutation rate of human immunodeficiency virus type 1 than that predicted from the fidelity of purified reverse transcriptase , 1995, Journal of virology.

[13]  K. Livak,et al.  Oligonucleotides with fluorescent dyes at opposite ends provide a quenched probe system useful for detecting PCR product and nucleic acid hybridization. , 1995, PCR methods and applications.

[14]  Tuofu Zhu,et al.  Virus Population Homogenization following Acute Human Immunodeficiency Virus Type 1 Infection , 2002, Journal of Virology.

[15]  E. Holmes,et al.  Convergent and divergent sequence evolution in the surface envelope glycoprotein of human immunodeficiency virus type 1 within a single infected patient. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[16]  S. Hammer,et al.  Antiretroviral therapy for HIV infection in 1997. Updated recommendations of the International AIDS Society-USA panel. , 1998, JAMA.

[17]  J. Heeney,et al.  A strategy for cloning infectious molecular clones of retroviruses from serum or plasma. , 2000, Journal of virological methods.

[18]  J. Mellors,et al.  Genetic correlates of in vivo viral resistance to indinavir, a human immunodeficiency virus type 1 protease inhibitor , 1996, Journal of virology.

[19]  C. Kuiken,et al.  HIV sequence databases. , 2003, AIDS reviews.

[20]  K Bebenek,et al.  The accuracy of reverse transcriptase from HIV-1. , 1988, Science.

[21]  S. Hammer,et al.  The Relation between Baseline HIV Drug Resistance and Response to Antiretroviral Therapy: Re-Analysis of Retrospective and Prospective Studies Using a Standardized Data Analysis Plan , 2000, Antiviral therapy.

[22]  L. P. Zhao,et al.  HIV Quasispecies and Resampling , 1996, Science.

[23]  T. Merigan,et al.  A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy , 2000 .

[24]  S. Paul,et al.  Hiv Resistance Testing , 2003 .

[25]  D. Richman,et al.  Nevirapine-resistant human immunodeficiency virus: kinetics of replication and estimated prevalence in untreated patients , 1996, Journal of virology.

[26]  S. Hammer,et al.  Detection of drug-resistant minority variants of HIV-1 during virologic failure of indinavir, lamivudine, and zidovudine. , 2004, The Journal of infectious diseases.

[27]  Diana D. Huang,et al.  Underestimation of HIV type 1 drug resistance mutations: results from the ENVA-2 genotyping proficiency program. , 2002, AIDS research and human retroviruses.

[28]  T. Merigan,et al.  Multiple Concurrent Reverse Transcriptase and Protease Mutations and Multidrug Resistance of HIV-1 Isolates from Heavily Treated Patients , 1998, Annals of Internal Medicine.

[29]  J. Coffin,et al.  HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy , 1995, Science.

[30]  B. Rewari,et al.  Antiretroviral Therapy for HIV Infection , 2007 .

[31]  P Balfe,et al.  Analysis of sequence diversity in hypervariable regions of the external glycoprotein of human immunodeficiency virus type 1 , 1990 .

[32]  M. Mouroux,et al.  Re-occurrence of HIV-1 drug mutations after treatment re-initiation following interruption in patients with multiple treatment failure. , 2001, AIDS.

[33]  Victor DeGruttola,et al.  Dual vs single protease inhibitor therapy following antiretroviral treatment failure: a randomized trial. , 2002, JAMA.

[34]  H. Agut,et al.  From RNA to quasispecies: a DNA polymerase with proofreading activity is highly recommended for accurate assessment of viral diversity. , 2003, Journal of virological methods.

[35]  Gary Collins,et al.  Structured treatment interruption in patients with multidrug-resistant human immunodeficiency virus. , 2003, The New England journal of medicine.

[36]  A. Leigh Brown,et al.  Independent evolution of the env and pol genes of HIV‐1 during zidovudine therapy , 1996, AIDS.

[37]  S. Paul,et al.  HIV resistance testing. A clinical tool. , 2003, New Jersey medicine : the journal of the Medical Society of New Jersey.

[38]  K. Metzner,et al.  Emergence of minor populations of human immunodeficiency virus type 1 carrying the M184V and L90M mutations in subjects undergoing structured treatment interruptions. , 2003, The Journal of infectious diseases.

[39]  K. Hertogs,et al.  Clinical and laboratory guidelines for the use of HIV-1 drug resistance testing as part of treatment management: recommendations for the European setting , 2001 .

[40]  J. Schapiro,et al.  Drug-resistance genotyping in HIV-1 therapy: the VIRAD APT randomi sed controlled trial , 1999, The Lancet.

[41]  E. Domingo,et al.  Pol gene quasispecies of human immunodeficiency virus: mutations associated with drug resistance in virus from patients undergoing no drug therapy , 1995, Journal of virology.

[42]  R Hoh,et al.  Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia. , 2001, The New England journal of medicine.

[43]  Rodrigo Lopez,et al.  Multiple sequence alignment with the Clustal series of programs , 2003, Nucleic Acids Res..

[44]  R. Laufs,et al.  Reappearance of HIV multidrug-resistance in plasma and circulating lymphocytes after reintroduction of antiretroviral therapy. , 2002, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[45]  G. Learn,et al.  Evolution of human immunodeficiency virus type 1 envelope sequences in infected individuals with differing disease progression profiles. , 1998, Virology.

[46]  Jacques Izopet,et al.  Changes in Human Immunodeficiency Virus Type 1 Populations after Treatment Interruption in Patients Failing Antiretroviral Therapy , 2001, Journal of Virology.

[47]  L. Menéndez-Arias Molecular basis of fidelity of DNA synthesis and nucleotide specificity of retroviral reverse transcriptases. , 2002, Progress in nucleic acid research and molecular biology.

[48]  V. Pathak,et al.  Retroviral mutation rates and reverse transcriptase fidelity. , 2003, Frontiers in bioscience : a journal and virtual library.

[49]  J. Corbeil,et al.  Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy , 1994, Journal of virology.